Clinical Trials Logo

Parkinsons Disease With Dementia clinical trials

View clinical trials related to Parkinsons Disease With Dementia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03774459 Completed - Clinical trials for Parkinsons Disease With Dementia

ANAVEX2-73 Study in Parkinson's Disease Dementia

Start date: July 9, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

NCT ID: NCT00988117 Completed - Clinical trials for Parkinsons Disease With Dementia

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

Start date: April 2010
Phase: Phase 4
Study type: Interventional

This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems. Rivastigmine (also sold under the name Exelon) is an FDA approved medication used for the treatment of mild to moderate Alzheimer's Disease (AD) and memory or thinking problems due to Parkinson's disease. Recently a rivastigmine patch was developed, which has shown similar effectiveness with fewer side effects and increased caregiver preference when compared to capsules. This is an open-label 12 week study where 15 subjects diagnosed with Parkinson's Disease who have mild to moderate memory and/or thinking complaints will be treated with the rivastigmine patch at UCSF. This study also analyzes the mechanism by which the rivastigmine patch works in people with Parkinson's disease and memory and/or thinking problems.